Overview
Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) . Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others . Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .
Indication
Pain, fever, and inflammation Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures . The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound). Other indications ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include: Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) . Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction . For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) . For the prevention of thromboembolism after hip replacement surgery . For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) . Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site . Important note regarding use of the extended-release formulation In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .
Associated Conditions
- Acute Coronary Syndrome (ACS)
- Anxiety
- Atherothrombotic cerebral infarction
- Cardiovascular Disease (CVD)
- Cardiovascular Events
- Cardiovascular Mortality
- Colorectal Adenomas
- Colorectal Cancer
- Common Cold
- Coronary artery reocclusion
- Death
- Dyspeptic signs and symptoms
- Fever
- Flu caused by Influenza
- Headache
- Heterozygous Familial Hypercholesterolemia (HeFH)
- Inflammation
- Juvenile Idiopathic Arthritis (JIA)
- Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
- Menstrual Pain
- Migraine
- Morbidity
- Mucocutaneous Lymph Node Syndrome
- Muscle Contraction
- Myalgia
- Myocardial Infarction
- Myocardial Infarction (MI), first occurrence
- Neuropathic Pain
- Pain
- Pain caused by Common Cold
- Pain caused by Rheumatism
- Pericarditis
- Polycythemia Vera (PV)
- Pre-Eclampsia
- Rheumatism
- Rheumatoid Arthritis
- Rhino Sinusitis
- Severe Pain
- Spondyloarthropathies
- Stroke
- Systemic Lupus Erythematosus
- Tension Headache
- Thromboembolism
- Thrombosis
- Toothache
- Transient Ischemic Attack
- Vascular Death
- Venous Thromboembolism
- Acute Inflammation
- Articular inflammation
- Atherothrombotic events
- Death caused by Myocardial Infarction
- Fever or influenza-like illness
- Moderate Pain
- Recurrent Ischemic Stroke
Clinical Trials
View More Clinical Trials
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2020/09/02 | Phase 3 | Withdrawn | |||
2020/09/01 | Phase 2 | Completed | |||
2020/08/07 | Phase 4 | UNKNOWN | Xijing Hospital | ||
2020/08/06 | Phase 4 | UNKNOWN | |||
2020/08/04 | Phase 3 | Terminated | Frank C Sciurba | ||
2020/07/21 | Phase 4 | Recruiting | |||
2020/07/10 | Phase 2 | UNKNOWN | |||
2020/07/09 | Early Phase 1 | ENROLLING_BY_INVITATION | |||
2020/07/02 | Phase 4 | Terminated | |||
2020/06/16 | Phase 1 | UNKNOWN |
FDA Drug Approvals
View More FDA Approvals
Sign in to access additional FDA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
View More EMA Approvals
Sign in to access additional EMA-approved drug information with detailed regulatory data.
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
View More HSA Approvals
Sign in to access additional HSA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
View More NMPA Approvals
Sign in to access additional NMPA-approved drug information with detailed regulatory data.
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Aspirin Enteric Capsules | 国药准字H10970345 | 化学药品 | 胶囊剂 | 9/24/2020 | |
| Aspirin Enteric Capsules | 国药准字H20143276 | 化学药品 | 胶囊剂 | 9/24/2020 | |
| Aspirin Enteric Capsules | 国药准字H10970344 | 化学药品 | 胶囊剂 | 9/24/2020 | |
| Aspirin Enteric Capsules | 国药准字H11022562 | 化学药品 | 胶囊剂 | 11/27/2020 | |
| Aspirin Enteric Capsules | 国药准字H11022455 | 化学药品 | 胶囊剂(肠溶) | 11/26/2020 | |
| Aspirin Enteric Capsules | 国药准字H50021943 | 化学药品 | 胶囊剂 | 7/30/2020 | |
| Aspirin Enteric Capsules | 国药准字H32026549 | 化学药品 | 胶囊剂 | 7/14/2020 | |
| Aspirin Enteric Capsules | 国药准字H42022876 | 化学药品 | 胶囊剂 | 9/7/2020 | |
| Aspirin Enteric Capsules | 国药准字H11022459 | 化学药品 | 胶囊剂 | 11/27/2020 | |
| Aspirin Enteric Capsules | 国药准字H42022843 | 化学药品 | 胶囊剂 | 9/29/2020 |
PPB Drug Approvals
View More PPB Approvals
Sign in to access additional PPB-approved drug information with detailed regulatory data.
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
View More TGA Approvals
Sign in to access additional TGA-approved drug information with detailed regulatory data.
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.